Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis – maintenance of healing and symptom relief

Summary Background Dexlansoprazole MR, a modified‐release formulation of dexlansoprazole, an enantiomer of lansoprazole, effectively heals erosive oesophagitis. Aim To assess dexlansoprazole MR in maintaining healed erosive oesophagitis. Methods Patients (n = 451) with erosive oesophagitis healed in either of two dexlansoprazole MR healing trials randomly received dexlansoprazole MR 60 or 90 mg or placebo once daily in this double‐blind trial. The percentage of patients who maintained healing at month 6 was analysed using life table and crude rate methods. Secondary endpoints were percentages of nights and of 24‐h days without heartburn based on daily diaries. Results Dexlansoprazole MR 60 and 90 mg were superior to placebo for maintaining healing (P